



СРПСКИ АРХИВ
ЗА ЦЕЛОКУПНО ЛЕКАРСТВО
SERBIAN ARCHIVES
OF MEDICINE

Address: 1 Kraljice Natalije Street, Belgrade 11000, Serbia

☎ +381 11 4092 776, Fax: +381 11 3348 653

E-mail: office@srpskiarhiv.rs, Web address: www.srpskiarhiv.rs

Paper Accepted*

ISSN Online 2406-0895

Case Report / Приказ болесника

Jelena Vasiljević^{1,2,*}, Jelica Pantelić^{1,2}, Jelena Mirković¹, Leila Al Barri³, Igor Kovačević^{1,2}

**Photocoagulation for retinal hemangioblastoma in
Von Hippel–Lindau disease**

Ласерфотокоагулација за ретинални хемангиобластом у
Вон Хипел–Линдауовој болести

¹University Clinical Centre of Serbia, Clinic for Eye Diseases, Belgrade, Serbia;

²University of Belgrade, Faculty of Medicine, Belgrade, Serbia;

³Victor Babes University of Medicine and Pharmacology, Department of Ophthalmology Timisoara, Romania

Received: May 26, 2023

Revised: October 11, 2023

Accepted: October 16, 2023

Online First: November 7, 2023

DOI: <https://doi.org/10.2298/SARH230526094V>

* **Accepted papers** are articles in press that have gone through due peer review process and have been accepted for publication by the Editorial Board of the *Serbian Archives of Medicine*. They have not yet been copy-edited and/or formatted in the publication house style, and the text may be changed before the final publication.

Although accepted papers do not yet have all the accompanying bibliographic details available, they can already be cited using the year of online publication and the DOI, as follows: the author's last name and initial of the first name, article title, journal title, online first publication month and year, and the DOI; e.g.: Petrović P, Jovanović J. The title of the article. Srp Arh Celok Lek. Online First, February 2017.

When the final article is assigned to volumes/issues of the journal, the Article in Press version will be removed and the final version will appear in the associated published volumes/issues of the journal. The date the article was made available online first will be carried over.

***Correspondence to:**

Jelena B. VASILJEVIĆ

University Clinical Centre of Serbia, Eye Clinic, Belgrade, Serbia

E-mail: bkjelena@gmail.com

Photocoagulation for retinal hemangioblastoma in Von Hippel–Lindau disease

Ласерфотокоагулација за ретинални хемангиобластом у Вон Хипел–Линдауовој болести

SUMMARY

Introduction Von Hippel–Lindau disease is a hereditary, autosomal dominant, tumor syndrome with predisposition to development of various benign and malignant tumors. Retinal hemangioblastoma is often the presenting manifestation.

We report a case of Von-Hippel–Lindau disease in a 13-year-old girl with bilateral eye involvement.

Case Outline The patient was referred to the Eye Clinic, University Clinical Center of Serbia with diagnosis of Coats disease. Clinical examination revealed that best corrected visual acuity was 20/20 on her right eye, while her left eye showed counting fingers at twenty centimeters distance. Dilated funduscopy of the right eye revealed multiple tortuous feeding vessels leading to orange-reddish, sharply demarcated multiple lesions on the far periphery of the upper retina, corresponding to retinal hemangioblastoma. Left eye showed edematous optic nerve head, tortuous retinal vessels, exudates, and retinal detachment including macula. Considering that patient had multiple bilateral retinal hemangioblastomas and that her father had pathohistologically proven brain hemangioblastoma and numerous visceral tumors, Von Hippel–Lindau disease was assumed. Focal argon laser photocoagulation was performed in the region of all visible vascular tumors and feeding vessels in the right eye. Patient's visual acuity remained unchanged five months after the disease detection.

Conclusion The importance of education about dominant inheritance pattern of Von Hippel–Lindau disease cannot be overemphasized. Role of an ophthalmologist is critical in early diagnosis of both retinal hemangioblastoma and Von Hippel–Lindau disease.

Keywords: Von Hippel–Lindau disease, retinal hemangioblastoma, photocoagulation

САЖЕТАК

Увод Вон Хипел–Линдауова болест је аутозомно доминантно наследни туморски синдром са пре-диспозицијом за развој различитих бенигних и малигних тумора. Ретинални хемангиобластом је често прва манифестација болести. Приказујемо случај Вон Хипел–Линдауове болести код 13-годишње девојчице са захватањем оба ока.

Приказ болесника Пацијенткиња је упућена на Клинику за очне болести, Универзитетског Клиничког центра Србије са дијагнозом Коатсове болести. Клинички преглед показао је најбоље кориговану видну оштрину 20/20 на десном оку, а на левом оку бројање прстију на удаљености од двадесет центиметара. Преглед десног ока у мидријазу показао је бројне извијугане исхрађујуће крвне судове који су водили до бројних наранџасто-црвенкастих, оштро ограничених лезија на крајњој периферији горње ретине, који су одговарали ретиналним хемангиобластомима. Лево око је показало оток главе очног нерва, извијугане крвне судове, ексудате и аблацију ретине која је захватала макулу. Узимајући у обзир да је пацијенткиња имала бројне обостране ретиналне хемангиобластоме и да је њен отац имао патохистолошки доказан хемангиобластом мозга као и разне висцералне туморе, постављена је сумња на Вон Хипел–Линдауову болест. Фокална аргон ласерфотокоагулација је учињена у регији свих видљивих васкуларних тумора и исхрађујућих крвних судова на десном оку. Видна оштрина је остала непромењена пет месеци након откривања болести.

Закључак Значај едукације о доминантном типу наслеђивања Вон Хипел–Линдауове болести не може бити пренаглашен. Улога офталмолога је кључна у раној дијагнози како ретиналног хемангиобластома тако и Вон Хипел–Линдауове болести.

Кључне речи: Вон Хипел–Линдауова болест; ретинални хемангиобластом; фотокоагулација

INTRODUCTION

Von Hippel–Lindau disease (VHL) is a hereditary, autosomal dominant, tumor syndrome. Patients are predisposed to develop various benign and malignant tumors, especially retinal hemangioblastomas (RH), central nervous system (CNS)

hemangioblastomas and renal tumors, however, other neoplasms can also occur including adrenal gland, pancreatic, inner ear, epididymal and endolymphatic sac tumors. The disease arises from a VHL tumor suppressor gene mutation located on the third chromosome. It usually presents in early adulthood. The penetrance is over 90% until the seventh decade [1, 2]. Incidence varies internationally from around 1 in 36.000 to 1 in 91.000 [1].

Retinal hemangioblastoma is often the presenting manifestation of the disease [2]. Clinically, the tumor appears as red, orange or pink, well-demarcated oval lesions, with tortuous and dilated feeding vessels. The peripheral retina and the optic nerve head (ONH) can be affected. Exudation is often seen around the lesion and in the macular region [1, 3]. Bilateral involvement and multiple RH are usual [3, 4].

Diagnosis and screening of VHL demand a multidisciplinary approach in which an ophthalmologist plays an important role. Timely diagnosis is essential since the disease is both vision and lifethreatening. Genetic testing and clinical assessment are recommended in patients with known family history even when asymptomatic, as well as in all patients with hemangioblastoma. Screening consists of regular physical evaluation, ophthalmic and audiological examination, brain and abdominal magnetic resonance imaging (MRI), all of these beginning from early childhood [1, 2].

We report a case of VHL in a 13-year-old girl with bilateral eye involvement.

CASE REPORT

A 13-year-old girl was urgently referred from a regional eye center to the Eye Clinic, University Clinical Center of Serbia with retinal detachment in the left eye and diagnosis of Coats disease. Medical, ocular and family history were taken from the girl's mother. She reported that girl was healthy, had no known medical conditions, the delivery was in term and complete immunization was performed. The history of ocular diseases and trauma was also

negative. While taking a detailed family history, we found out that the girl's father had died two months prior from kidney disease. Additionally, seventeen years ago he had a brain tumor surgery.

Clinical examination revealed that best corrected visual acuity measured on Snellen chart was 20/20 on her right eye, while her left eye showed counting fingers at twenty centimeters distance. Intraocular pressures were within normal limits. The left pupil was slightly wider and the light reflex was slower. Both anterior segments and eye motility were normal. Dilated indirect fundoscopy of the right eye revealed multiple tortuous feeding vessels leading to orange-reddish, sharply demarcated multiple lesions on the far periphery of the upper retina, corresponding to RH. The macular region and ONH of the right eye were unaffected (Figure 1). Left eye showed edematous ONH, tortuous retinal vessels, exudates, and retinal detachment including macula (Figure 2). Optical coherence tomography and optical coherence tomography angiography could not be performed on the left eye due to massive exudation and retinal detachment, while both were normal on the right eye. The patient was admitted to the hospital for further evaluation and treatment. On admission, b-scan ultrasonography and fluorescein angiography were conducted. Ultrasonography of the right eye was normal, while on the left eye a hemorrhagic retinal detachment of the lower retinal parts, including the macular region, with a big intraretinal cyst was described. Fluorescein angiography of the right eye showed tortuous feeding vessels with early and marked late phase leakage from the clinically visible tumors (Figure 3). Left fluorescein angiography corresponded with clinically described retinal detachment with diffuse leakage from retinal vessels of the upper, attached retina and underlying RH (Figure 4). Prompt focal argon laser photocoagulation (LPC) was performed in the region of all visible vascular tumors in the right eye in order to prevent visual loss on the only functionally eye (Figure 5). Considering that patient had multiple bilateral RH and that her father had a brain lesion and

kidney disease, VHL was assumed. During hospitalization, brain MRI, pediatric and nephrological physical exams were obtained, which were normal.

On the first follow-up, ten days after discharge, partial vitreous hemorrhage and bleeding over the tumor were observed. Laser photocoagulation spots were partially pigmented. The visual acuity on the right eye was 20/20. Left eye findings were unchanged. A thorough inspection of the father's medical documentation revealed that he had pathohistologically proven brain hemangioblastoma. Furthermore, he was diagnosed with multiple kidney and pancreatic tumors and suspected to have VHL while additional diagnostics could not be performed due to his poor general health, at that time. On the second and third follow-ups (a month and two months after discharge, respectively), partial tumor regression was observed, still, additional LPC treatment was applied to the multiple tumor lesions and feeding vessels of the right eye to ensure the prevention of further complications (Figure 6). Regular monthly follow-ups have been conducted and the patient's visual acuity on the right eye remained stable five months after the disease detection. This case report was approved by the institutional ethics committee, and written consent was obtained from the patient for the publication of this case report and any accompanying images.

DISCUSSION

Retinal hemangioblastoma can be either sporadic or, more often, a part of the VHL. Danish retrospective national study from 2018. reported genetically confirmed VHL in 84% of their patients with RH [5]. These findings highlight the importance of thinking about VHL in all patients with RH and distinguishing cases with sporadic disease of those associated with VHL, since malignant visceral neoplasms could be present in the latter form.

Von Hippel–Lindau disease is typically confirmed through genetic testing. Individuals with first-degree relatives suffering from VHL should also undergo genetic testing in order to

detect those with the risk of tumor evolution and provide them with an appropriate surveillance. If genetic testing is unavailable, the diagnosis can be established based on clinical criteria of at least one VHL manifestation and a first-degree relative with confirmed disease or at least two VHL tumors affecting different organs, of which at least one has to be hemangioblastoma [1, 2]. According to these standards, we can conclude that our patient's father could have been clinically diagnosed with VHL, as well as our patient based on RH findings and positive family history. The patient's mother was unaware of the disease's hereditary nature and the need for surveillance of all descendants. When family history is present, screening should ideally consist of genetic testing and/or evaluation of organ systems disease's-connected to VHL. The screening protocol for RH starts from the first year and includes a dilated indirect fundoscopy once a year [1, 2, 6, 7].

Retinal hemangioblastoma represents one of the most common tumors found in VHL, occasionally diagnosed in childhood as presented in our case [1, 2]. The average age of presentation is 25 years, being the lowest compared to other VHL-related tumors. The earliest reported onset was in the first year of life [6]. Additionally, patients diagnosed with VHL have an earlier occurrence of RH compared to sporadic cases. Consequently, RH is the first sign of VHL in up to 77% of patients, which emphasizes the important role of an ophthalmologist in disease detection [2–6]. A cohort study that consisted of 335 subjects, examined the epidemiology of RH in VHL and found no correlation with age, sex and laterality. The same study noticed a higher prevalence of bilateral RH (57.9 %), a predilection for peripheral retina compared to juxta-papillary RH (84.7 %), and an average tumor number of 2.5 ± 1.8 per eye [8]. Our patient had bilateral disease and multiple tumors with typical appearance, affecting the peripheral retina, which encompasses characteristic clinical presentation of VHL. Still, she was referred to our institution with suspicion of Coats disease. When retinal exudation is present, Coats disease and retinal macroaneurysm can be a

differential diagnosis, however, our patient did not have visible retinal exudation on her right eye. Other conditions that may resemble RH include retinal vasoproliferative tumors, microvascular abnormalities, congenital retinal arteriovenous malformations and papillitis, juxta-papillar choroiditis or choroidal neovascularization in case of juxta-papillary RH [7]. For that reason, examination of the dilated fundus is important to identify any existing changes, especially in the far periphery where changes can easily be overlooked.

Retinal hemangioblastoma is benign in terms of its biological features. It can, however, lead to visual impairing complications which correlate with the tumor size. Exudation from the lesion, vitreous hemorrhage and traction of the nearby retina are the commonest [8, 9]. It is a slow-growing tumor that sometimes allows observation with close follow-up instead of prompt treatment. Even though, treatment is required in most cases. Specific guidelines for the treatment of RH have not been published yet, therefore decision on the most appropriate treatment method is based on clinical experience and literature data. Laser photocoagulation, with the aim to destruct the tumor or the feeding vessels, is the mainstay of treatment, except for RH near the macula or ONH [10, 11]. Krivosic et al. treated 100 eyes with LPC alone and reported success with inactivating RH in 97% of subjects while maintaining baseline visual acuity during the next four and a half years. The success rate was absolute in cases of small RH (less than 1 disc diameter) [9]. Laser photocoagulation carries a risk of bleeding or subretinal exudation and cannot be used when complications, such as exudative or tractional retinal detachment occur [12]. Therefore, early intervention, when the tumor is still small, can significantly affect the outcome. Other treatment modalities include cryotherapy, photodynamic therapy, transpupillary thermotherapy, radiotherapy, intravitreal anti-vascular endothelial growth factor therapy and pars plana vitrectomy [10-12]. A recent review report suggests that the tumor size followed by tumor location and concomitant complications are the main factors in choosing a therapeutic option. They propose that small peripheral tumors

(less than 1.5 millimeters) without tumor-related complications should be treated with LPC. Medium-sized lesions (between 1.5 and 4.5 millimeters) could be managed with either cryotherapy, transpupillary thermotherapy or radiotherapy. For tumors larger than 4.5 millimeters and those with vitreoretinal complications, vitreorectomy is preferable [11]. Juxtapapillary RH are a specific therapeutic challenge. Photodynamic therapy in these cases can be beneficial [9, 12]. Combined therapies are also reported [9, 13]. Our patient's right eye was successfully treated with LPC and the visual acuity was unchanged during a five-month long follow-up. However, she still has profound visual impairment in her left eye, which could have been prevented if ophthalmological examinations had been performed as recommended, from the first year of life.

The importance of education about the disease-dominant inheritance pattern and adequate screening of patients with VHL and their close relatives cannot be overemphasized. The role of an ophthalmologist is critical in early diagnosis of both RH and VHL since the disease can be blinding or even lethal.

Conflict of interest: None declared.

REFERENCES

1. Binderup ML, Smerdel M, Borgwadt L, Nielsen SS, Madsen MG, Møller HU, Kiilgaard JF, Friis-Hansen L, Harbud V, Cortnum S, Owen H. von Hippel-Lindau disease: Updated guideline for diagnosis and surveillance. *European Journal of Medical Genetics*. 2022 Aug 1;65(8):104538. [DOI: 10.1016/j.ejmg.2022.104538] [PMID: 35709961]
2. Aronow ME, Wiley HE, Gaudric A, Krivosic V, Gorin MB, Shields CL, Shields JA, Jonasch EW, Singh AD, Chew EY. von Hippel-Lindau disease: update on pathogenesis and systemic aspects. *Retina*. 2019 Dec 1;39(12):2243-53. [DOI: 10.1097/IAE.0000000000002555] [PMID: 31095066]
3. Huang Y, Hu W, Huang X. Retinal hemangioblastoma in a patient with Von Hippel-Lindau disease: A case report and literature review. *Frontiers in Oncology*. 2022;6:122. [DOI: 10.3389/fonc.2022.963469] [PMID: 36408156]
4. Murro V, Lippera M, Mucciolo DP, Canu L, Ercolino T, De Filipo G, Giorgio D, Traficante G, Sodi A, Virgili G, Giansanti F. Outcome and genetic analysis of patients affected by retinal capillary hemangioblastoma in von Hippel Lindau syndrome. *Molecular Vision*. 2021;27:542. [PMID: 34566400]
5. Binderup ML, Stendell AS, Galanakis M, Møller HU, Kiilgaard JF, Bisgaard ML. Retinal hemangioblastoma: prevalence, incidence and frequency of underlying von Hippel-Lindau disease. *British Journal of Ophthalmology*. 2018 Jul 1;102(7):942-7. [DOI: 10.1136/bjophthalmol-2017-310884] [PMID: 28972023]
6. Varshney N, Kebede AA, Owusu-Dapaah H, Lather J, Kaushik M, Bhullar JS. A review of Von Hippel-Lindau syndrome. *Journal of Kidney Cancer and VHL*. 2017;4(3):20. [DOI: 10.15586/jkcvhl.2017.88] [PMID: 28785532]
7. Karimi S, Arabi A, Shahraki T, Safi S. Von Hippel-Lindau disease and the eye. *Journal of ophthalmic & vision research*. 2020 Jan;15(1):78. [DOI: 10.18502/jovr.v15i1.5950] [PMID: 32095212]
8. Wong WT, Agrón E, Coleman HR, Tran T, Reed GF, Csaky K, Chew EY. Clinical characterization of retinal capillary hemangioblastomas in a large population of patients with von Hippel-Lindau disease. *Ophthalmology*. 2008 Jan 1;115(1):181-8. [DOI: 10.1016/j.ophtha.2007.03.009] [PMID: 17543389]
9. Krivosic V, Kamami-Levy C, Jacob J, Richard S, Tadayoni R, Gaudric A. Laser photocoagulation for peripheral retinal capillary hemangioblastoma in von Hippel-Lindau disease. *Ophthalmology Retina*. 2017 Jan 1;1(1):59-67. [DOI: 10.1016/j.oret.2016.08.004] [PMID: 31047395]
10. Wiley HE, Krivosic V, Gaudric A, Gorin MB, Shields C, Shields J, Aronow ME, Chew EY. Management of retinal hemangioblastoma in von Hippel-Lindau disease. *Retina (Philadelphia, Pa.)*. 2019 Dec;39(12):2254. [DOI: 10.1097/IAE.0000000000002572] [PMID: 31259811]
11. Hajjaj A, van Overdam KA, Gishti O, Ramdas WD, Kilic E. Efficacy and safety of current treatment options for peripheral retinal haemangioblastomas: a systematic review. *Acta Ophthalmologica*. 2022 Feb;100(1):e38-46. [DOI: 10.1111/aos.14865] [PMID: 33834636]
12. Huang C, Tian Z, Lai K, Zhong X, Zhou L, Xu F, Yang H, Lu L, Jin C. Long-term therapeutic outcomes of photodynamic therapy-based or photocoagulation-based treatments on retinal capillary hemangioma. *Photomedicine and Laser Surgery*. 2018 Jan 1;36(1):10-7. [DOI: 10.1089/pho.2017.4296] [PMID: 29068750]
13. Tyagi S, Kumar KC, Saluja K. How 'eye'helped in von Hippel-Lindau syndrome. *European Journal of Ophthalmology*. 2023 Jan;33(1):NP5-9. [DOI: 10.1177/11206721211035632] [PMID: 34308676]




Figure 1. Color photos of the right eye on admission where single retinal hemangioblastomas is clearly identifiable in extreme superior periphery (arrow)



Figure 2. Color photos of the left eye on admission showing retinal detachment with underlying retinal hemangiomas (arrows)



Figure 3. Fluorescein angiography of the right eye on admission, showing areas of leakage in the superior periphery which corresponds to retinal hemangioblastomas (arrows)




Figure 4. Fluorescein angiography of the left eye of typical peripheral retinal hemangioblastomas showing early hyperfluorescence and marked late phase leakage while subretinal exudation was seen as blocked hyperfluorescence



Figure 5. Color photo of the right fundus after the first focal laser photocoagulation treatment




Figure 6. Color photos of the right eye after additional focal laser photocoagulation treatments a month (top row) and two months (bottom row) after discharge